Wisp’s menopause consultation page puts several estrogen and progesterone options within one service. It also directs readers toward additional care for vaginal symptoms. That breadth makes the appointment relevant, but it does not tell a reader whether an added medicine would address symptoms, accompany another treatment or be unnecessary.
This September 29, 2026 review examines the public consultation offer and service terms. It follows the explanation from treatment goal to named prescription and pharmacy purchase. No patient assessment, selected medicine, appointment availability or insurance claim was tested.
The care menu establishes an offer, not a treatment sequence
The consultation page names estrogen patches, gels and oral options, and lists micronized progesterone, Provera and other oral options under its progesterone heading. This supports a relevant prescribing service. It does not establish that every named option has the same active ingredient, formulation or place in a treatment plan.
The clinician’s explanation should identify the proposed medicine rather than repeat the category heading. A patient would need its actual name and purpose before comparing it with an existing prescription. The site’s short menu does not disclose the complete ingredients, manufacturer or pharmacy stock for the eventual product, and it cannot serve as a substitute for that prescription record.
Start with the problem the consultation is intended to address
ACOG’s menopause therapy information describes different treatment effects and distinguishes systemic therapy from locally directed vaginal treatment. Wisp’s range of services should be read against those separate purposes. A complaint discussed at a menopause visit does not itself establish which hormone, if any, should be prescribed.
Our systemic-estrogen discussion explains why the accompanying progestogen question needs context. Stella’s assessment considers a different provider’s sample combinations. In both settings, a useful explanation connects the specific treatment to the intended outcome and describes the role of any second medicine. This review does not select a combination from the examples.
A vaginal-care link does not settle the progesterone question
Wisp’s public offer points to further hormonal and nonhormonal care for vaginal dryness. That link is not evidence that every vaginal treatment produces systemic exposure or requires an additional progesterone prescription.
The NAMS 2020 consensus abstract states that progestogen is not indicated with low-dose vaginal estrogen, while explicitly limiting the evidence: endometrial safety was not studied in clinical trials beyond one year. It also notes insufficient safety data in women with breast cancer. Those qualifications belong beside the statement. The local-estrogen guide therefore asks about the exact preparation and clinical context, without converting an exception into personal clearance.
History should explain the recommendation rather than become a checkbox rule
ACOG’s surgical overview distinguishes operations involving the uterus, cervix and ovaries. A brief recollection of having had surgery may not identify the procedure adequately. The Wisp pages reviewed here do not show the entire questionnaire or establish how a clinician would investigate those details.
The history questions after hysterectomy can help frame a conversation without predicting its result. A missing uterus is not permission for this publication to dismiss every possible reason for a medicine. Equally, a general wellness rationale does not prove a universal need. Joi’s review examines that second issue through its own published claims.
The monthly care charge leaves a pharmacy decision outstanding
The menopause offer starts at $33 per month for the consultation, follow-ups and monthly access to the care team. It separately says prescribed medicines are paid for at a local pharmacy. That service amount is therefore not an all-inclusive progesterone treatment price.
The page describes same-day prescription transmission and availability across all fifty states. Transmission is different from dispensing: the chosen pharmacy still needs the actual prescription and its own price and stock information. The public location statement does not establish that a particular patient can receive any listed medicine. A pharmacy charge, insurer decision and selected clinical outcome were not verified through a transaction. The consultation page’s FAQ headings do not provide complete eligibility answers in the reviewed public record. Its broad availability statement therefore leaves specific access questions unresolved instead of proving an unrestricted service.
Renewal terms concern the account, not the clinical reason for treatment
Under Wisp’s terms, prescription purchases require a clinician’s assessment and a valid prescription. The subscription language calls for cancellation at least forty-eight hours before the next refill or renewal period to avoid another periodic charge. The reviewed terms also describe renewal conditions rather than unlimited prescribing without further clinical review.
Product sales are generally final, with possible remedies such as refunds or replacements left to the stated circumstances and Wisp’s discretion. These provisions should not be expanded into a promise about a local pharmacy’s separate policy. Nor does ending a paid account answer what clinical follow-up is needed; those are different conversations with different responsible parties.
Access to follow-ups cannot establish the cause of bleeding
ACOG’s bleeding information explains why abnormal changes around menopause and bleeding afterward need professional assessment. A new symptom cannot be evaluated by comparing prices, reading a hormone category or assuming an accompanying medicine has removed every concern.
The unexpected-bleeding discussion keeps that question with a qualified professional. Wisp’s advertised follow-ups may provide a route for communication, but the offer does not prove the response time or examination appropriate to a particular concern. The unresolved part of this review is deliberately concrete: who will explain the prescription’s purpose, assess a change and arrange another setting of care when necessary?
Sources behind this article
Use the original documents to check their scope. A provider’s offer and a named medicine’s label establish different facts.
- Wisp: menopause consultationDated provider offer naming micronized progesterone and other oral options; starting care charge excludes local-pharmacy medicine, eligibility FAQ extraction incomplete · Checked 2026-09-28
- ACOG: Hormone Therapy for MenopauseUS specialty patient guidance; systemic and local exposure, treatment goals and clinical assessment, no personal regimen · Checked 2026-09-29
- North American Menopause Society: 2020 Genitourinary Syndrome of Menopause position statementPublished professional consensus abstract only; low-dose vaginal therapy distinction, lack of endometrial trials beyond one year and breast-cancer evidence limits · Checked 2026-09-29
- ACOG: HysterectomyUS specialty patient guidance; uterus, cervix and ovary procedures distinguished, no treatment decision from surgery name alone · Checked 2026-09-29
- Wisp: terms of useDated platform transaction terms; prescription renewal review, 48-hour cancellation and discretionary product remedies; not individual legal advice · Checked 2026-09-28
- ACOG: Perimenopausal Bleeding and Bleeding After MenopauseUS specialty patient guidance reviewed February 2024; bleeding changes require professional assessment, not a site-generated workup or medication adjustment · Checked 2026-09-29